Biotech · Private company
Adaptimmune
Track this companyFree. Adds Adaptimmune to your Dealase workspace and tells you when its record changes.
Clinical trials130 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- ADP-A2M4 in combination with pembrolizumab.Phase 2 · Head and Neck CancerClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified ADP-A2M4CD8 cellsPhase 2 · Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹TPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- NYESO-1c259 T cellsPhase 2 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Treatment with NY-ESO-1c259-modified T cellsPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified AFPᶜ³³²T cellsPhase 1 · Hepatocellular CancerClinicalTrials.gov · fetched Nov 12, 2026
- Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cellsPhase 1 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶TPhase 1 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- GSK3845097Phase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- GSK3901961Phase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- GSK4427296Phase 1 · NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Genetically engineered T Cell ReceptorsSolid and Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)PHASE2 · TERMINATED · started Sep 15, 2021ClinicalTrials.gov NCT04752358 · fetched Nov 12, 2026
- Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung CancerPHASE1 · TERMINATED · started Mar 9, 2021ClinicalTrials.gov NCT06048705 · fetched Nov 12, 2026
- Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid TumorsPHASE1 · TERMINATED · started Dec 21, 2020ClinicalTrials.gov NCT04526509 · fetched Nov 12, 2026
- Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell LiposarcomaPHASE1 · TERMINATED · started Dec 21, 2020ClinicalTrials.gov NCT05943990 · fetched Nov 12, 2026
- SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck CancerPHASE2 · WITHDRAWN · started Jul 2, 2020ClinicalTrials.gov NCT04408898 · fetched Nov 12, 2026
- Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell ReceptorsTERMINATED · started Feb 28, 2018ClinicalTrials.gov NCT03391791 · fetched Nov 12, 2026
- AFPᶜ³³²T in Advanced HCCPHASE1 · COMPLETED · started May 8, 2017ClinicalTrials.gov NCT03132792 · fetched Nov 12, 2026
- MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersPHASE1 · COMPLETED · started Oct 1, 2016ClinicalTrials.gov NCT02989064 · fetched Nov 12, 2026
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility DeterminationCOMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02636855 · fetched Nov 12, 2026
- MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLCPHASE1 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02592577 · fetched Nov 12, 2026
- CT Antigen TCR-Engineered T Cells for MyelomaPHASE1_PHASE2 · TERMINATED · started Oct 15, 2013ClinicalTrials.gov NCT01892293 · fetched Nov 12, 2026
- CT Antigen TCR-redirected T Cells for Ovarian Cancer.PHASE1_PHASE2 · COMPLETED · started Jul 9, 2013ClinicalTrials.gov NCT01567891 · fetched Nov 12, 2026
- Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic MelanomaPHASE1_PHASE2 · TERMINATED · started Jun 1, 2011ClinicalTrials.gov NCT01350401 · fetched Nov 12, 2026